1061.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally...

Stats
Today's Volume	36 000.00
Average Volume	111 264
Market Cap	1.60B
P/E	6.41
ATR14	HKD0 (0.00%)

Essex Bio-Technology Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Essex Bio-Technology Ltd Financials

Annual	2022
Revenue:	HKD1.32B
Gross Profit:	HKD1.19B (90.26%)
EPS:	HKD0.390

Q2	2018
Revenue:	HKD0.00
Gross Profit:	HKD0.00 (0.00%)
EPS:	HKD0

Q2	2017
Revenue:	HKD0.00
Gross Profit:	HKD0.00 (0.00%)
EPS:	HKD0

Q2	2012
Revenue:	HKD0.00
Gross Profit:	HKD0.00 (0.00%)
EPS:	HKD0

Essex Bio-Technology Ltd Financials DIVIDENDS

(Q3/19) 2019-08-29	(Q2/20) 2020-05-14	(Q2/21) 2021-05-14	(Q3/21) 2021-08-30	(Q2/22) 2022-05-04	(Q3/22) 2022-09-05	(Q2/23) 2023-06-13	(Q3/23) 2023-08-29
HKD0.0350 (Paid: 2019-09-20)	HKD0.0500 (Paid: 2020-06-02)	HKD0.0500 (Paid: 0000-00-00)	HKD0.0400 (Paid: 0000-00-00)	HKD0.0550 (Paid: 0000-00-00)	HKD0.0400 (Paid: 0000-00-00)	HKD0.0250 (Paid: 0000-00-00)	HKD0.0450 (Paid: 0000-00-00)

Essex Bio-Technology Ltd

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.

Estimated
1061.HK Next Dividend
(2024-05-17) HKD0.0468 Probabilty 100 %